Phathom Pharmaceuticals has begun patient screening in a Phase 3 trial of an investigational as-needed treatment regimen for adults with non-erosive GERD. The study marks a new step in its digestive disorders pipeline as management heads to investor conferences in September.
published
Phathom Pharmaceuticals has begun patient screening in a Phase 3 trial of an investigational as-needed treatment regimen for adults with non-erosive GERD. The study marks a new step in its digestive disorders pipeline as management heads to investor conference
Latest documented BWB result
See Billy's timestamped results and follow-through.
Review the latest gains posts, original timestamps, and proof images published by Banking With Billy.
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.